Study of Chronic Antihistamine and Amantadine Treatments in COVID-19 Outcomes

What this Trial Is About

Researchers are evaluating how chronic treatment with antihistamines or amantadine might affect the course of COVID-19 infection. The study aims to measure rates of symptomatic COVID-19 infection, hospital admissions, survival, post-COVID syndrome, and thrombosis in patients receiving these treatments. Data will be compared with age-matched groups from the general population in the Terrassa Health Consortium. The study observes patients already taking antihistamines or amantadine as a chronic treatment, tracking their health outcomes related to COVID-19 from March 2020 onward. Comparisons will be made between these patients and others within the same age groups from the general population. No new treatments are given this is an observational study assessing existing medication use. Participants are monitored for hospital admissions, survival, symptomatic infection, and complications like post-COVID syndrome and thrombosis. The study uses health records to collect this data and compares outcomes between the treatment group and general population over time. The total study period covers from March 2020 to February 2028, with ongoing data collection and analysis.

Antihistamines, Amantadine and Evolution of COVID-19